Literature DB >> 1464657

Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets.

S A Rivkees1, G el-Hajj-Fuleihan, E M Brown, J D Crawford.   

Abstract

We report the development of severe tertiary hyperparathyroidism in three girls treated for familial hypophosphatemic rickets and characterize parathyroid function in vivo and in vitro. All patients had been previously treated with relatively large doses of inorganic phosphorus (125 mm/day) and ergocalciferol or calcitriol for several years and had radiographic evidence of long-standing hyperparathyroidism. Even in the presence of extremely elevated PTH levels, oral phosphate lowered serum calcium levels in vivo and further stimulated PTH secretion. Profound multiglandular parathyroid hyperplasia was found in each patient at surgery. Examination of the secretory characteristics of the excised parathyroid tissue revealed that either relatively high calcium concentrations were generally needed to suppress PTH secretion or PTH secretion was not suppressible. Caution is recommended when relatively large doses of phosphate are used to treat familial hypophosphatemic rickets.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1464657     DOI: 10.1210/jcem.75.6.1464657

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  23 in total

1.  Outcome of total parathyroidectomy and autotransplantation as treatment of secondary and tertiary hyperparathyroidism in children and adults.

Authors:  A J Kievit; J G M Tinnemans; M M Idu; J W Groothoff; S Surachno; D C Aronson
Journal:  World J Surg       Date:  2010-05       Impact factor: 3.352

Review 2.  The long-term complications of the inherited tubulopathies: an adult perspective.

Authors:  Maryam Khosravi; Stephen B Walsh
Journal:  Pediatr Nephrol       Date:  2014-02-25       Impact factor: 3.714

3.  Development of tertiary hyperparathyroidism after phosphate supplementation in oncogenic osteomalacia.

Authors:  Q L Huang; D S Feig; M E Blackstein
Journal:  J Endocrinol Invest       Date:  2000-04       Impact factor: 4.256

4.  Hypophosphatemic rickets: results of a long-term follow-up.

Authors:  Maria Helena Vaisbich; Vera H Koch
Journal:  Pediatr Nephrol       Date:  2005-10-27       Impact factor: 3.714

Review 5.  FGF23 and syndromes of abnormal renal phosphate handling.

Authors:  Clemens Bergwitz; Harald Jüppner
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

6.  Approach to the hypophosphatemic patient.

Authors:  Erik A Imel; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2012-03       Impact factor: 5.958

7.  Secondary hyperparathyroidism as a palpable intrathyroid parathyroid gland in a patient with hypophosphatemic osteomalacia.

Authors:  Deng-Huang Su; Kuo-Meng Liao; Ying-Chun Chang; Keh-Sung Tsai
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

8.  X-linked hypophosphatemic rickets (PHEX mutation): A case report and literature review.

Authors:  Badi Alenazi; M A Maleque Molla; Abdullah Alshaya; Mahmoud Saleh
Journal:  Sudan J Paediatr       Date:  2017

9.  Hypertension in hypophosphatemic rickets--role of secondary hyperparathyroidism.

Authors:  Uri S Alon; Roshanak Monzavi; Marc Lilien; Majid Rasoulpour; Mitchell E Geffner; Ora Yadin
Journal:  Pediatr Nephrol       Date:  2003-01-18       Impact factor: 3.714

Review 10.  Physiology and pathophysiology of the calcium-sensing receptor in the kidney.

Authors:  Daniela Riccardi; Edward M Brown
Journal:  Am J Physiol Renal Physiol       Date:  2009-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.